Point72 Asia Singapore Pte. Ltd. Sells 30,936 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Point72 Asia Singapore Pte. Ltd. lowered its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 78.3% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 8,568 shares of the company’s stock after selling 30,936 shares during the period. Point72 Asia Singapore Pte. Ltd.’s holdings in Dianthus Therapeutics were worth $235,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Quest Partners LLC increased its stake in shares of Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after purchasing an additional 1,124 shares during the period. Fred Alger Management LLC grew its holdings in Dianthus Therapeutics by 52.5% in the 3rd quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock valued at $264,000 after buying an additional 3,316 shares in the last quarter. SG Americas Securities LLC bought a new position in Dianthus Therapeutics during the 2nd quarter worth $112,000. MetLife Investment Management LLC lifted its holdings in shares of Dianthus Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 13,939 shares of the company’s stock worth $382,000 after buying an additional 7,854 shares in the last quarter. Finally, American Century Companies Inc. boosted its position in shares of Dianthus Therapeutics by 38.6% in the second quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock valued at $788,000 after acquiring an additional 8,473 shares during the period. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Trading Down 0.5 %

Shares of DNTH opened at $25.57 on Wednesday. Dianthus Therapeutics, Inc. has a 52-week low of $6.58 and a 52-week high of $33.77. The business’s fifty day moving average is $26.65 and its 200-day moving average is $26.53.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. Research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Oppenheimer raised their price target on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research report on Monday, November 11th. Wedbush lowered their target price on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Friday, August 9th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Finally, Raymond James raised their price objective on Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Dianthus Therapeutics has an average rating of “Buy” and an average target price of $46.43.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.